AIMI (AIM ImmunoTech) Other Operating Expense : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 1995. Start your Free Trial

What is AIM ImmunoTech Other Operating Expense?

AIM ImmunoTech's Other Operating Expense for the three months ended in Dec. 2024 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

AIM ImmunoTech's quarterly Other Operating Expense stayed the same from Jun. 2024 ($-0.00 Mil) to Sep. 2024 ($-0.00 Mil) but then increased from Sep. 2024 ($-0.00 Mil) to Dec. 2024 ($0.00 Mil).

AIM ImmunoTech's annual Other Operating Expense increased from Dec. 2022 ($-0.00 Mil) to Dec. 2023 ($0.00 Mil) but then declined from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($-0.00 Mil).

AIM ImmunoTech Other Operating Expense Historical Data

The historical data trend for AIM ImmunoTech's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Other Operating Expense Chart

AIM ImmunoTech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Operating Expense

Get a 7-Day Free Trial

AIM ImmunoTech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Operating Expense	Get a 7-Day Free Trial															-	-	-	-	-

AIM ImmunoTech Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

AIM ImmunoTech Other Operating Expense Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (OTCPK:AIMI) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

0A4Y:UK HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Executives

Thomas K. Equels	director, officer: Vice Chairman of Board	2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
William M Mitchell	director	2117 SW HWY 484, OCALA FL 34473
Stewart Appelrouth	director	2117 SW HIGHWAY 484, OCALA FL 34473
Rodino Peter W. Iii	director	2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Nancy Bryan	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Ellen M Lintal	officer: CFO	2117 SW HWY 484, OCALA FL 34473
David R Strayer	other: Medical Director	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Wayne S. Springate	officer: VP of Operations	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Adam Pascale	officer: CFO	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Ralph Christopher Cavalli	officer: VP, Quality Control	510 MURDOCH ROAD, PHILADELPHIA PA 19119
Russel J Lander	officer: VP of Process/QualityAssurance	784 BAEDER ROAD, JENKINTOWN PA 19046
Robert Iv Dickey	officer: Senior Vice President	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bernhardt Charles Thomas Iii	officer: CFO	23 BIRCH ROAD, MALVERN PA 19355
Steven D Spence	director	250 EAST 54TH STREET APARTMENT 36C, NEW YORK NY 10022
Anthony Bonelli	officer: President & COO	P.O. BOX 521, NEW VERNON NJ 07976